-

Forge Biologics to Present at 2021 Cell & Gene Meeting on the Mesa

CEO to discuss company’s AAV gene therapy manufacturing and company achievements over the past 12 months

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., CEO, President and Co-Founder, will discuss Forge’s robust AAV manufacturing solutions, proprietary technology advancements, and clinical development during a company presentation at Cell & Gene Meeting on the Mesa on October 12 at 5:00 p.m. PT.

Dr. Miller will also join a panel of gene therapy experts for a discussion on “Dosing & Redosing in Gene Therapy,” October 14 at 11:00 a.m. PT.

The conference will take place October 12-14, 2021, at the Park Hyatt Aviara, in Carlsbad, California. To learn more about the event and registration, please visit: https://meetingonthemesa.com.

Forge will be taking meetings during Meeting on the Mesa. Please contact John Maslowski, Chief Commercial Officer, at CD@forgebiologics.com if you are interested in connecting and learning more about how Forge’s manufacturing solutions can support your gene therapy program.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Forge Biologics


Release Summary
Forge to Present at 2021 Cell & Gene Meeting on the Mesa
Release Versions

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Restore Vision and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

TOKYO & COLUMBUS, Ohio--(BUSINESS WIRE)--Restore Vision, Inc. (“Restore Vision”), a clinical-stage biotechnology company advancing gene therapies for retinal disorders, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to support RV-001, Restore Vision’s investigational GPCR-based optogenetic AAV gene therapy for patients with retinitis pigmentosa. Through this collabor...

Skylark Bio and Forge Biologics Announce Strategic AAV Development and cGMP Manufacturing Partnership Supporting Skylark’s Clinical Development

CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--Skylark Bio (“Skylark”), a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a strategic AAV development and cGMP manufacturing partnership. Under the partnership, Forge is providing Skylark with process development, current good manufacturing practice (cGMP) manufacturi...

Forge Biologics Announces Seven Presentations at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver seven presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15, 2026, in Boston. The presentations include two technical sessions, co-chairing an oral abstract session, and four scientific posters. “As the gene therapy field enters a crit...
Back to Newsroom